Stock Information

• Baird Maintains Outperform on Alto Neuroscience, Lowers Price Target to $38
  Thu, Apr 2, 2026 1:58 PM
• Crude Oil Rises Sharply; Acuity Shares Fall After Q2 Results
  Thu, Apr 2, 2026 1:30 PM
• HC Wainwright & Co. Reiterates Buy on Alto Neuroscience, Maintains $50 Price Target
  Thu, Apr 2, 2026 12:24 PM
• Jones Trading Maintains Buy on Alto Neuroscience, Lowers Price Target to $44
  Thu, Apr 2, 2026 10:44 AM
• Wedbush Maintains Neutral on Alto Neuroscience, Lowers Price Target to $21
  Thu, Apr 2, 2026 9:08 AM
• Alto Neuroscience, Immunovant And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
  Thu, Apr 2, 2026 8:02 AM
• Alto Neuroscience shares are trading lower after the company announced topline data from its Phase 2 proof-of-concept clinical trial evaluating ALTO-101 did not achieve statistical significant on primary electroencephalography or cognitive endpoints versus placebo.
  Thu, Apr 2, 2026 8:01 AM
• Why Globalstar Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket
  Thu, Apr 2, 2026 5:10 AM
• 12 Health Care Stocks Moving In Wednesday's After-Market Session
  Wed, Apr 1, 2026 5:05 PM
• Alto Neuroscience Announces Topline Data From Phase 2 POC Clinical Trial Evaluating ALTO-101 For Treatment Of CIAS; ALTO-101 Did Not Achieve Statistical Significance On Primary EEG Or Cognitive Endpoints Versus Placebo
  Wed, Apr 1, 2026 4:32 PM

Financial data not available